Genzyme CEO Nets $9.3 Million From Options

In the past few days, Genzyme CEO Henri Termeer exercised options worth about $15.4 million on the open market, netting some $9.3 million from the series of transactions, according to a form filed with the SEC today. From the filing, it looks like that leaves Termeer owning some 631,000 shares directly, and no more options. Genzyme (NASDAQ: GENZ) closed today at $75.97, near its one-year high of $76.90.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy